Cord serum metabolic signatures of future progression to immune-mediated diseases

Tuulia Hyötyläinen*, Bagavathy Shanmugam Karthikeyan, Tannaz Ghaffarzadegan, Eric W. Triplett, Matej Orešič, Johnny Ludvigsson

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

1 Citation (Scopus)
10 Downloads (Pure)


Previous prospective studies suggest that progression to autoimmune diseases is preceded by metabolic dysregulation, but it is not clear which metabolic changes are disease-specific and which are common across multiple immune-mediated diseases. Here we investigated metabolic profiles in cord serum in a general population cohort (All Babies In Southeast Sweden; ABIS), comprising infants who progressed to one or more immune-mediated diseases later in life: type 1 diabetes (n = 12), celiac disease (n = 28), juvenile idiopathic arthritis (n = 9), inflammatory bowel disease (n = 7), and hypothyroidism (n = 6); and matched controls (n = 270). We observed elevated levels of multiple triacylglycerols (TGs) an alteration in several gut microbiota related metabolites in the autoimmune groups. The most distinct differences were observed in those infants who later developed HT. The specific similarities observed in metabolic profiles across autoimmune diseases suggest that they share specific common metabolic phenotypes at birth that contrast with those of healthy controls.

Original languageEnglish
Article number106268
Number of pages17
Issue number3
Publication statusPublished - 17 Mar 2023
MoE publication typeA1 Journal article-refereed


  • Health sciences
  • Human metabolism
  • Immunology
  • Lipidomics
  • Metabolomics


Dive into the research topics of 'Cord serum metabolic signatures of future progression to immune-mediated diseases'. Together they form a unique fingerprint.

Cite this